Tebotelimab Biosimilar Bispecific scFv Antibody (PD-1 × LAG-3) for Research

Cat No.: GMP-Bios-ab-556

Pre-Made Tebotelimab biosimilar, Bispecific scFv with Crossover, Anti-PDCD1/PD-1;LAG3 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tebotelimab (MGD013) is a bispecific monoclonal antibody. It is anticipated that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-556-1mg 1mg
GMP-Bios-ab-556-10mg 10mg
GMP-Bios-ab-556-100mg 100mg
GMP-Bios-ab-556-xmg >100mg



Product Details

Products Name (INN Index) Pre-Made Tebotelimab biosimilar, Bispecific scFv with Crossover, Anti-PDCD1/PD-1;LAG3 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 therapeutic antibody
INN Name Tebotelimab
TargetPD-1;LAG3
FormatBispecific scFv with Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesMacroGenics
Conditions Approvedna
Conditions ActiveGastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours
Conditions Discontinuedna
Development Techna



About target - PDCD1

1. Protein Programmed cell death 1 ligand 1

2. Gene CD274

3. Organism Homo sapiens (Human)

Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).

The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).